Source: Cardiovascular Business, by Michael Walter

Hydroxychloroquine is not associated with an abnormal amount of arrhythmic events among COVID-19 patients, according to a brand new analysis out of Europe.

The study, published in EP Europace, includes data from 649 COVID-19 patients treated with the drug. All patients were enrolled from March 10 to April 10, 2020, and the most common symptoms were fever, dry cough and dyspnea. Patients were treated in a variety of clinical settings, including ICUs, medical wards and even at home. While 53.8% of patients were given hydroxychloroquine alone, 30% of patients received two QT-prolonging drugs in total. Another 13.6% of patients received three QT-prolonging drugs.

Overall, the authors said hydroxychloroquine was only associated with “modest QTc prolongation.” The overall major ventricular arrhythmia rate was just 1.1%. From their perspective—they were specifically focused on its arrhythmic safety—the medication “seems to be safe, regardless of the clinical setting in which it is started” as long as an adequate ECG monitoring strategy is in place.

The team emphasized that it was not ruling on the overall “clinical efficacy” of hydroxychloroquine with this research.

“In order to draw definitive conclusions regarding the impact of hydroxychloroquine on COVID-19 patients, results from one of the several ongoing trials are needed,” wrote lead author Alessio Gasperetti, MD, of the Heart Rhythm Center in Milan, Italy, and colleagues. “On the other hand, this study aims to present the available data regarding the hydroxychloroquine arrhythmic safety profile in COVID-19 patients, to provide physicians with real-world evidence coming from three different clinical settings, upon which to build a more evidence-based decision-making process.”

Of all the potential COVID-19 treatments discussed throughout the last several months, none have grabbed more mainstream attention than hydroxychloroquine.

Click here to read the full EP Europace study.


Belgium Study 8,075 patients: Low HCQ doses resulted in lower mortality in Covid patients

Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

How hydroxychloroquine works at the cellular level

Why Is The Media Suppressing Information About Hydroxychloroquine’s Effectiveness Against COVID?

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »